(Total Views: 512)
Posted On: 03/08/2017 8:50:37 AM
Post# of 23059
OCRX..halted ...resumed.
V OCR-002 statistically significantly normalized ammonia faster than standard
of care
Ammonia reduction statistically significantly correlated with clinical
improvement in HE symptoms
Ocera plans to meet with FDA in Q3 2017 to inform development paths forward for
IV OCR-002
Company presentation scheduled for today, March 8, 2017 at 11:20 AM ET
PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C. , March 08, 2017 (GLOBE
NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage
biopharmaceutical company focused on acute and chronic orphan liver diseases,
today announced it will report additional encouraging results from its Phase 2b
STOP-HE study of intravenous (IV) OCR-002 in hospitalized patients with Hepatic
Encephalopathy (HE) at the Cowen and Company 37th Annual Healthcare Conference
at 11:20 AM Eastern Time today.
V OCR-002 statistically significantly normalized ammonia faster than standard
of care
Ammonia reduction statistically significantly correlated with clinical
improvement in HE symptoms
Ocera plans to meet with FDA in Q3 2017 to inform development paths forward for
IV OCR-002
Company presentation scheduled for today, March 8, 2017 at 11:20 AM ET
PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C. , March 08, 2017 (GLOBE
NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage
biopharmaceutical company focused on acute and chronic orphan liver diseases,
today announced it will report additional encouraging results from its Phase 2b
STOP-HE study of intravenous (IV) OCR-002 in hospitalized patients with Hepatic
Encephalopathy (HE) at the Cowen and Company 37th Annual Healthcare Conference
at 11:20 AM Eastern Time today.
(0)
(0)
Nothing I state is intended to be a recommendation to buy or sell, opinion only. Readers are solely responsible for how they use the information.
